retatrutide mechanism triple agonist glp-1 gip glucagon receptor Retatrutide: How the Compares to Tirzepatide Retatrutide: How Triple GLP-1/GIP/Glucagon Receptor
Description
Finerenone is contraindicated in people with an eGFR below 25 mL/min/1.73 m 2
She cited GLP-1 receptor agonists as a key therapy that can promote weight loss and benefit multiple conditions
Limitations of the Current Evidence Base No scientific review is complete without transparent discussion of what evidence can and cannot answer: Thyroid cancer is rare
In RANDs 2025 survey of users, ~52% reported nausea and ~34% diarrhea (mostly mild), and ~20% reported vomiting
